Grace Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Grace Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Grace Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$4.16M, a 73.8% decline year-over-year.
  • Grace Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$13.4M, a 65.5% increase year-over-year.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$12.9M, a 69.7% increase from 2022.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$42.4M, a 332% decline from 2021.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$9.82M, a 50.1% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.